M&A Deal Summary |
|
|---|---|
| Date | 2020-11-09 |
| Target | Absorption Systems |
| Sector | Life Science |
| Buyer(s) | Pharmaron |
| Deal Type | Add-on Acquisition |
| Deal Value | 138M USD |
| Advisor(s) | Fairmount Partners (Financial) Troutman Pepper Hamilton Sanders (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2004 |
| Sector | Life Science |
| Employees | 22,908 |
| Revenue | 12.3B CNY (2024) |
Pharmaron is a publicly owned, premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of R&D service capabilities ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism, clinical pharmacology, clinical analytical sciences, clinical CRO and SMO, to chemical & pharmaceutical development. With over 10,000 employees, and operations in China, the United States, and the United Kingdom, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan, and China. Pharmaron was founded in 2004 and is based in Beijing, China.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 5 |
| Sector: Life Science M&A | 4 of 5 |
| Type: Add-on Acquisition M&A Deals | 3 of 4 |
| State: Pennsylvania M&A | 1 of 1 |
| Country: United States M&A | 3 of 3 |
| Year: 2020 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-02-28 |
Shin Nippon Biomedical Laboratories Clinical Pharmacology Center
Baltimore, United States Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, Inc. (SNBL CPC) is a clinical pharmacology facility located in the University of Maryland BioPark in Baltimore, Maryland, USA. The state of the art facility and equipment is bolstered by a vibrant research community. SNBL CPC specializes in complex Phase I-II trials, including TQT/Phase 1 QT de-risking, first-In-human (FIH), Japanese Bridging and Phase II Proof of Concept (POC) studies in therapeutics areas including immunology/infectious disease, neurology, respiratory, dermatology and more. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-10-28 |
Biortus
Jiangyin, China Biortus is a contract research organization that provides integrated drug discovery services from gene synthesis to structure determination. The Company’s capabilities include protein production, biochemical and cellular assays, compound screening, X-ray crystallography, and cryo-electron microscopy. Biortus was founded in 2009 and is headquartered in Wuxi, China. |
Buy | - |
